Effect of Pomegranate Peel Consumption on Liver Enzymes, Lipid Profile, Liver Steatosis, and Hs‐CRP in Patients With Non‐alcoholic Fatty Liver Disease: A Double‐Blind, Placebo‐Controlled, Randomized Clinical Trial
Authors: Baghdadi Ghazal , Shidfar Farzad , Mokhtare Marjan , Sarbakhsh Parvin , Agah Shahram 
Published: November 2024

The most prevalent chronic liver disease for which there is currently no proven treatment is non‐alcoholic fatty liver disease (NAFLD). An incomplete understanding of the underlying mechanisms of NAFLD may be the cause. The onset and development of this illness appear to be influenced by problems with lipid metabolism, insulin resistance, oxidative stress, and inflammation. Considering the antioxidant properties of pomegranate peel extract, this study was conducted to determine the effects of pomegranate peel consumption on some metabolic features in patients with NAFLD. Our hypothesis is that pomegranate peel can improve the grade of fatty liver, liver enzymes, lipid profile, serum high‐sensitivity C‐reactive protein (hs‐CRP), and anthropometric indices. The aim of this study was to investigate the efficacy of pomegranate peel extract in NAFLD patients. This double‐blind randomized clinical trial was conducted on 46 patients with NAFLD. Patients were randomly assigned to intervention group (n = 23) and placebo group (n = 23). Patients in the pomegranate peel group consumed two capsules, each containing 500 mg pomegranate peel extract daily as a part of low‐calorie diet (i.e., 500‐deficit calorie diet) for 10 weeks. While patients in the control group followed the low calorie diet and two capsules containing 500 mg maltodextrin. At the beginning and end of the study, demographic information, anthropometric indices, food intake, physical activity level, grade of fatty liver, liver enzymes, lipid profile, and serum high‐sensitivity C‐reactive protein (hs‐CRP) were measured. Food intake was measured by 24‐h food recall questionnaires and physical activity was measured by the International Physical Activity Questionnaire (IPAQ). Analysis of food recall questionnaire was done using Nutritionist IV program. Statistical analysis was performed using SPSS software (version 22), and a p value < 0.05 was defined as statistically significant. Of 46 patients, 42 of them completed the trial. At the end of the trial, pomegranate peel group had significantly higher reduction in TG (triglycerides), ALT(<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bing.com/ck/a?!&&p=269da4c190440323JmltdHM9MTY5NTg1OTIwMCZpZ3VpZD0wMjk2OTZjZS1kY2FmLTZkNWQtMDQ1Mi04Njk3ZGQzNDZjN2MmaW5zaWQ9NTE1Ng&ptn=3&hsh=3&fclid=029696ce-dcaf-6d5d-0452-8697dd346c7c&psq=alaninaminotransferase&u=a1aHR0cHM6Ly93d3cud2VibWQuY29tL2RpZ2VzdGl2ZS1kaXNvcmRlcnMvYWxhbmluZS1hbWlub3RyYW5zZmVyYXNlLXRlc3Q&ntb=1">alanine aminotransferase), AST(aspartate transferase), hs‐CRP and also had higher significant increase in HDL‐C(high‐density lipoprotein cholesterol) compared to the control group (p = 0/02, p = 0/02, p = 0/01, p = 0/01, and p = 0/04, respectively). However, changes in LDL‐C, TC, ALP, GGT, and fatty liver grade were not significantly different between the two groups at the end of the study. The current study indicates that pomegranate peel extract has a favorable effect on liver enzymes, lipid profile, and serum high‐sensitivity C‐reactive protein (hs‐CRP) in patients with NAFLD. To support these results, trials examining various dosages over longer time periods are necessary.